Disease · MONDO_0004949

neoplasm of mature B-cells

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. neoplasm of mature B-cells. Diseases, record MONDO_0004949. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004949

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: neoplasm of mature B-cells; Open Targets
Open Targets ID: MONDO_0004949; Open Targets
Other names: mature B-cell lymphocytic neoplasm, mature B-cell neoplasm; Open Targets
Disease Ontology: DOID:706; Disease Ontology
NCI Thesaurus: C27910; NCI Thesaurus
Highest stage of its drugs: Approval, for 4 of its 50 drugs, from DailyMed and FDA; Open Targets

Drugs50

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
IDELALISIB	CHEMBL2216870	Small molecule	Approval	DailyMed	2	1	1	Drugs and targets
BENDAMUSTINE HYDROCHLORIDE	CHEMBL1201734	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
COPANLISIB HYDROCHLORIDE	CHEMBL3545068	Small molecule	Approval	FDA	1	0	0	Drugs and targets
DUVELISIB MONOHYDRATE	CHEMBL5315125	Small molecule	Approval	FDA	1	0	0	Drugs and targets
BENDAMUSTINE	CHEMBL487253	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
DUVELISIB	CHEMBL3039502	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
UBLITUXIMAB	CHEMBL2108354	Antibody	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
UMBRALISIB	CHEMBL3948730	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
RITUXIMAB	CHEMBL1201576	Antibody	Phase 2	ClinicalTrials.gov	14	14	14	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 2	ClinicalTrials.gov	5	5	5	Drugs and targets

1 to 10 of 50

See all 50 drugs

Targets86

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PIK3CD	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	6	PI3-kinase p110-delta subunit inhibitor	Approval	https://conductscience.org/library/genes/5293	Drugs and targets
BTK	Tyrosine-protein kinase BTK	5	Tyrosine-protein kinase BTK inhibitor	Phase 2	https://conductscience.org/library/genes/695	Drugs and targets
MS4A1	B-lymphocyte antigen CD20	5	B-lymphocyte antigen CD20 binding agent	Phase 2/3	https://conductscience.org/library/genes/931	Drugs and targets
POLA1	DNA polymerase (alpha/delta/epsilon)	3	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/5422	Drugs and targets
POLA2	DNA polymerase (alpha/delta/epsilon)	3	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/23649	Drugs and targets
POLD1	DNA polymerase (alpha/delta/epsilon)	3	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/5424	Drugs and targets
POLD2	DNA polymerase (alpha/delta/epsilon)	3	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/5425	Drugs and targets
POLD3	DNA polymerase (alpha/delta/epsilon)	3	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/10714	Drugs and targets
POLD4	DNA polymerase (alpha/delta/epsilon)	3	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/57804	Drugs and targets
POLE	DNA polymerase (alpha/delta/epsilon)	3	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/5426	Drugs and targets

1 to 10 of 86

See all 86 targets

Trials37

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00946023	Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab	Phase 2	135	2018-07-24	Lymphoma, B-cell Lymphoma, Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia	CYCLOPHOSPHAMIDE, FLUDARABINE, RITUXIMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT00481871	Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies	Phase 1/2	119	2012-09-18	Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma, Peripheral T-cell Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia	GEMCITABINE HYDROCHLORIDE, PRALATREXATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT01980628	Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma	Phase 2	63	2017-02-10	Marginal Zone Lymphoma, B-cell Lymphoma	IBRUTINIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT03520920	BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)	Phase 2	41	2021-10-28	Marginal Zone Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma	RITUXIMAB, ZANUBRUTINIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT00453102	Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma	Phase 2	18	2016-01-01	Marginal Zone Lymphoma	IBRITUMOMAB TIUXETAN, RITUXIMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT02933320	BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia	Phase 1/2	14	2021-07-08	B-cell Lymphoma, Chronic Lymphocytic Leukaemia, Waldenström Macroglobulinemia	BI-1206, RITUXIMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT01121757	Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma	Phase 2	11	2015-05-07	Follicular Lymphoma, Marginal Zone Lymphoma	AZACITIDINE, LENALIDOMIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT03269552	Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma	Phase 2	4	2020-01-18	Marginal Zone Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Marginal Zone Lymphoma, Refractory Waldenstrom Macroglobulinemia, Waldenstrom Macroglobulinemia	CARFILZOMIB, RITUXIMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT04189952	Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma	Phase 2	2	2022-09-19	Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Marginal Zone Lymphoma	ACALABRUTINIB, CARBOPLATIN, ETOPOSIDE, IFOSFAMIDE, RITUXIMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT02793583	Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma	Phase 2/3	710		Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma	BENDAMUSTINE, UBLITUXIMAB, UMBRALISIB	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 37

See all 37 trials

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
1a-Azacitidine Followed by Lenalidomide vs 1b-Lenalidomide Followed by Azacitidine: Overall Response	1 of 6	0 of 3	9	NCT01121757	Trial comparisons
1a-Azacitidine Followed by Lenalidomide vs 1b-Lenalidomide Followed by Azacitidine: serious adverse events	2 of 6	2 of 3	9	NCT01121757	Trial comparisons
1a-Azacitidine Followed by Lenalidomide vs 1b-Lenalidomide Followed by Azacitidine: Overall Response	2 of 4	0 of 1	5	NCT01121757	Trial comparisons

Papers from its trials9

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
26588924	RESULT	1	PubMed
26183076	RESULT	1	PubMed
40610174	DERIVED	1	PubMed
38775302	DERIVED	1	PubMed
38598516	DERIVED	1	PubMed
33683917	DERIVED	1	PubMed
33227125	DERIVED	1	PubMed
28167659	DERIVED	1	PubMed
27482888	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004949

GET https://conductscience.org/api/diseases/v1/MONDO_0004949/drugs?page=2

API reference For AI assistants